Pemphigus Vulgaris: Autoimmune Acantholytic Disease, Oral Mucosal Involvement, and Immunosuppressive Management

Clinical Overview

Pemphigus vulgaris (PV) is a rare but serious autoimmune blistering disorder affecting skin and mucous membranes, characterized by acantholysis (loss of cell-to-cell adhesion) causing intraepidermal blister formation. This potentially life-threatening condition results from autoantibodies (IgG) against desmoglein 3 (mucosal involvement) and desmoglein 1 (cutaneous involvement), leading to antibody-mediated desmoglein destruction. Incidence 0.5-3.2 per million annually; higher in Middle Eastern, Jewish, Mediterranean, and Indian populations.

Epidemiology

Pemphigus vulgaris peak incidence 40-60 years. Male-to-female ratio 1:1. Higher prevalence in Ashkenazi Jews (1.6 per 100,000), Mediterranean populations, Indian subcontinent (1.6-3.2 per 100,000). HLA-DR4, -DQ2, -DQ8 associations. Oral mucosal involvement initial presentation 80-90% (often mistaken for canker sores/aphthous ulcers). Cutaneous disease develops 2-6 months after oral onset. Triggers: stress, infections (herpes simplex, tuberculosis), medications (ACE inhibitors, NSAIDs, penicillamine, captopril). Pre-treatment mortality 5-15%; with modern therapy <5%. Relapse rates 30-50% upon steroid tapering, necessitating long-term suppressive therapy.

Pathophysiology

Pemphigus vulgaris involves IgG autoantibodies against desmoglein 3 (transmembrane glycoprotein in desmosomes). Anti-desmoglein 3 antibodies alone cause mucosal-dominant disease; additional anti-desmoglein 1 antibodies cause mucocutaneous disease. Antibodies bind desmoglein, triggering complement activation, mast cell degranulation, and keratinocyte signaling (actin reorganization via Rho signaling). Result: loss of cell-to-cell adhesion creating intraepidermal acantholysis. Epithelial surfaces (oral mucosa, esophagus) particularly vulnerable due to constant mechanical trauma and high desmoglein 3 expression. Secondary infections common (Candida, bacteria) due to mucosal denudation. IgG anti-desmoglein 3 titers correlate with disease activity (higher titers = more severe disease).

Clinical Presentation

Oral mucosal involvement (present in 80-90% at diagnosis): painful erosions/ulcerations on buccal mucosa, palate, gingiva, tongue. Lesions bleed easily, impair swallowing/eating, and are persistent despite conventional ulcer treatment. Cutaneous involvement (develops 2-6 months later in mucosal-dominant PV): flaccid blisters rupturing easily into erosions. Distinct from bullous pemphigoid: blisters are FLACCID (rupture easily, leaving denuded surface) vs. tense bullae in pemphigoid. Pruritus typically absent; pain/tenderness prominent. Distribution: seborrheic areas (scalp, face, chest, intertriginous regions) initially; can progress to widespread involvement. Nikolsky sign positive (epidermis separates with lateral pressure). Secondary infections common, delaying healing. Esophageal involvement in 20-30%: dysphagia, odynophagia, stricture formation. Severe cases: marked fluid loss, infection, malnutrition, mortality risk.

Diagnosis

Diagnosis: clinical + serology. Mucosal/perilesional skin biopsy: histopathology shows intraepidermal acantholysis with "tombstone" or "row of tombstones" appearance (basal cells detach from suprabasal layers while remaining anchored to basement membrane). Direct immunofluorescence (DIF): intercellular IgG deposition in epidermis (distinct from basement membrane deposition in pemphigoid)—"tombstone" pattern. Serology: ELISA anti-desmoglein 3 (95% sensitivity), anti-desmoglein 1 (80% with mucocutaneous disease). Titers correlate with disease activity. Indirect immunofluorescence or immunoprecipitation on patient sera against keratinocyte antigens supportive.

Treatment Algorithm

First-Line - Systemic Corticosteroids: Prednisolone/prednisone 0.5-1.5 mg/kg/day (40-80mg typically), higher doses (1-2 mg/kg) for severe disease. Improvement expected within 1-3 weeks (lesion cessation, healing of existing lesions). Gradual taper by 5-10mg every 2-4 weeks based on clinical response and anti-desmoglein titers. Full remission requires 6-12 months minimum therapy. Major toxicity: opportunistic infections (Pneumocystis prophylaxis with TMP-SMX if CD4 <200 or high-dose corticosteroids), hyperglycemia, osteoporosis.

Steroid-Sparing Agents (Essential for Long-Term Management): Azathioprine 1-2.5 mg/kg/day: first-line steroid-sparing (60-75% response), reduces steroid requirements 50-60%, enables steroid discontinuation 30-50%. Requires 2-3 months for efficacy; must use with corticosteroids initially. Mycophenolate mofetil 2-3g daily: effective in 60-70%, alternative if azathioprine intolerant. Methotrexate 10-25mg weekly: effective in 50-60% (slower than azathioprine). Cyclosporine 3-5 mg/kg/day: reserved for azathioprine-refractory cases due to nephrotoxicity/hypertension risks. IVIG 2g/kg intravenous monthly: rapid anti-desmoglein antibody reduction (effective within days), used for rapidly progressive/severe disease. Rituximab (anti-CD20 B-cell monoclonal antibody) 375mg/m² weekly x 4: emerging highly effective agent (80-90% complete response in refractory PV), reduces antibody production. Cost and availability limit routine use.

Oral Mucosal Ulcer Management: Topical anesthetics (viscous lidocaine 2%) applied to ulcers for pain relief. Oral rinses: 0.1% triamcinolone or flucinonide 0.05% in saline, rinse 2-3 times daily (local steroid absorption minimal, safe adjunctive). Antimicrobial mouth rinses (chlorhexidine 0.12%) if secondary bacterial infection develops. Oral antifungal (clotrimazole 10mg troche 5 times daily) for Candida superinfection (develops in 50% of cases). Soft diet, avoid spicy foods.

Prognosis

Pemphigus vulgaris without treatment: 5-15% mortality (secondary infection, fluid loss, malnutrition). With corticosteroids: 90%+ achieve complete remission. Long-term remission: 30-50% achieve prolonged remission off all therapy; however, 50-70% require indefinite low-dose maintenance therapy. Relapse common (40-50%) upon steroid tapering, necessitating re-escalation. Azathioprine/mycophenolate addition permits steroid reduction/discontinuation. Mortality with modern therapy <5%; morbidity includes corticosteroid toxicity, infections, quality-of-life impact from oral ulcers.

When to See a Dermatologist

Urgent dermatology referral essential for suspected PV (oral erosions refractory to typical treatment warrant investigation). Dermatologists confirm diagnosis via biopsy/serology, initiate immunosuppression, and manage disease progression. Coordinate with rheumatology/internal medicine for systemic management and infection prophylaxis.

Frequently Asked Questions

Q: Is pemphigus vulgaris curable?
A: No cure exists; virus/autoimmunity remains lifelong. However, 30-50% achieve prolonged remission off all therapy. Majority (50-70%) require indefinite low-dose maintenance corticosteroids/azathioprine. "Remission" defined as absence of new lesions on stable low-dose therapy.

Q: How dangerous is pemphigus?
A: Without treatment, 5-15% mortality. With modern therapy, <5% mortality. Main risks: secondary infection (20-40% develop), malnutrition (difficulty swallowing), and corticosteroid toxicity with long-term therapy. Prognosis excellent with prompt diagnosis/treatment.

Q: Why are mouth sores not healing?
A: Pemphigus vulgaris causes autoimmune destruction of oral mucosa (antibodies against desmoglein 3). Standard mouth ulcer treatments ineffective; requires immunosuppression (corticosteroids, azathioprine). Topical steroids alone inadequate; systemic therapy essential.

Q: Can I stop corticosteroids eventually?
A: 30-50% eventually discontinue all therapy. However, 50-70% require indefinite maintenance (prednisolone 5-10mg daily + azathioprine). Gradual taper attempted; however, most require ongoing therapy to prevent relapse. Continue monitoring anti-desmoglein titers to guide therapy adjustment.

References